Editorial Podcasts

In today’s Pharma Pulse, industry leaders warn of serialization security issues and pharma companies brace for the 2033 NDC shift.

In today's Pharma Pulse, the FDA grants expanded approval for Imcivree, while new research highlights how optimizing pharmacy technician roles can significantly boost vaccine access and uptake.

In today's Pharma Pulse, the FDA grants a 54-day fast-track approval for high-dose Wegovy under a new priority program while a new report explores the economic pressures and chronic shortages destabilizing the U.S. generics market

In today's Pharma Pulse, the FDA approves Icotyde as the first targeted oral peptide therapy for moderate-to-severe plaque psoriasis, while Cold Chain Technologies prepares to debut its MedAssure orchestration platform at LogiPharma 2026

In today's Pharma Pulse, ongoing conflict in the Middle East disrupts critical pharmaceutical cold chains, while AstraZeneca and partners launch a new program to decarbonize industrial heat across global supply chains.

In today’s Pharma Pulse, the FDA expands a key biologic approval for pediatric patients, and new research highlights the success of pharmacist-led testing in rural communities.

In today’s Pharma Pulse, Eli Lilly issues a safety warning and SteinCares enters a licensing agreement with Shilpa Biologicals to expand biosimilar access in Latin America.

In today’s Pharma Pulse, the FDA launched a unified monitoring system to enable real-time adverse event reporting, and direct-to-employer drug purchasing models are emerging as companies look to bypass traditional intermediaries.

In today’s Pharma Pulse, the FDA approved Wellcovorin as the first therapy for an ultra-rare neurological disorder, and disparities in OTC naloxone access persist despite declining retail prices.

In today’s Pharma Pulse, Eli Lilly has launched the Employer Connect platform broadening access to Zepbound for U.S. workers, while Tandem Diabetes expands the reach of its Mobi insulin pump to Android smartphones.

In today’s Pharma Pulse, Antengene and UCB ink a $1.18 billion global deal for ATG-201 to target autoimmune diseases, while AI partnerships and Pharma 4.0 technologies accelerate drug development and manufacturing efficiency.

In today's Pharma Pulse, the FDA expands the pediatric indication for Juxtapid to treat rare homozygous familial hypercholesterolemia, while Novo Nordisk announces a major €432 million investment in its Irish facility to scale global oral GLP-1 production.

In today’s Pharma Pulse, the FDA grants priority review to a therapy for polycythemia vera, while Novo Nordisk receives expanded pediatric approval for its once-weekly growth hormone.

In today’s Pharma Pulse, the FDA grants a lightning-fast approval for Boehringer’s lung cancer therapy under its new priority program, while CMS Administrator Mehmet Oz launches a sweeping offensive against fraudulent billing.

A conversation with Kenco’s Tim McClatchy explores how pharmaceutical logistics providers are strengthening cybersecurity across manufacturer-to-home delivery networks, deploying AI to optimize operations, and adapting to evolving regulatory pressures shaping the future of healthcare supply chains.

In today’s Pharma Pulse, Eli Lilly’s orforglipron shows superior blood sugar control over oral semaglutide, while GSK secures a $950 million acquisition of 35Pharma.

In today’s Pharma Pulse, UK regulators seize thousands of fake weight loss pens, while new data reveals that the "miracle jab" is financially out of reach for nearly 70% of users.

In today’s Pharma Pulse, the FDA unveils a Plausible Mechanism framework to fast-track ultra-rare disease therapies, while Astellas partners with Vir Biotechnology in a massive $2.1 billion oncology collaboration.

In today’s Pharma Pulse, Eli Lilly launches the monthly Zepbound KwikPen to streamline obesity care, while Gilead Sciences moves to acquires Arcellx in a massive expansion of its cell therapy portfolio.

In today’s Pharma Pulse, BioNTech escalates its patent battle against Moderna over next-gen COVID shots, while a new pharmacist-led "PRIME" program proves a game-changer for prediabetes prevention.

In today’s Pharma Pulse, Johnson & Johnson commits over $1 billion to a new biomanufacturing site in Pennsylvania, while Hims & Hers enters a $1.15 billion agreement to acquire Australian telehealth leader Eucalyptus.

In today’s Pharma Pulse, the FDA shifts its stance on Moderna’s mRNA flu vaccine after an initial rejection, while Eli Lilly secures a major licensing deal for a promising anti-inflammatory antibody.

In today’s Pharma Pulse, HHS Secretary RFK Jr. centralizes department operations under CMS leadership, while a new telehealth model shows a 66% reduction in repeat ER visits for older adults.

In today’s Pharma Pulse, the Senate tackles the regulatory red tape driving physician burnout, while Edwards Lifesciences ends its anti-copycat policy to settle European Commission antitrust concerns.

In today’s Pharma Pulse, Eli Lilly amasses a record-breaking stockpile for its oral GLP-1, while new research reveals a 66% reduction in endometrial cancer risk for certain patients.

In today’s Pharma Pulse, bipartisan lawmakers target PBM vertical integration, while pharma giants race to secure tariff-exempt pricing deals.

In today’s Pharma Pulse, the FDA issues a rare “Refusal-to-File" for Moderna’s influenza vaccine, while new research confirms GLP-1s act as potent tools against chronic inflammation.

In today’s Pharma Pulse, the American College of Physicians issues a formal rejection of the term "provider," while Takeda partners with Iambic Therapeutics to accelerate small-molecule discovery through AI.